Head and neck cancer patients treated with concomitant chemoradiotherapy involving the oral cavity and oropharynx: is another choice possible than prophylactic gastrostomy?
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
medline:
5
4
2024
pubmed:
4
4
2024
entrez:
4
4
2024
Statut:
ppublish
Résumé
Recent recommendations on cachexia highlight, in head and neck cancers, the heterogeneity of studies, focusing on weight loss and sequelae including swallowing disorders. The current national guidelines emphasize that, in cases of concurrent chemoradiotherapy (cCRT) involving the oral cavity and oropharynx, prophylactic gastrostomy placement should be carried out systematically. We review why this technique is particularly relevant in this specific location for the feasibility of cCRT. A randomized trial is underway on swallowing disorders and the quality of life of patients after prophylactic vs. reactive gastrostomy in advanced oropharyngeal cancer patients treated with CRT. Concurrently, recent literature reviews emphasize the importance of the cumulative dose of chemotherapy for local control and survival. In cases of cCRT involving the oral cavity or the oropharynx, nutritional support could have a beneficial or detrimental impact on chemotherapy. Specifically for patients treated with cCRT involving the oral cavity and oropharynx, prophylactic gastrostomy would be able to fulfill the three objectives of local control, survival, and quality of life, minimizing complications related to nutritional support. Studies need to be more homogeneous. In clinical practice, nutrition should primarily assist in carrying out cancer treatment when survival is the main goal.
Identifiants
pubmed: 38573201
doi: 10.1097/CCO.0000000000001031
pii: 00001622-202405000-00003
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-135Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
INCA - Les cancers en France [Internet]. [cited 30 January 2023]. https://www.e-cancer.fr/ressources/cancers_en_france/.
Economopoulou P, Kotsantis I, Psyrri A. Special issue about head and neck cancers: HPV positive cancers. Int J Mol Sci 2020; 21:E3388.
Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945–1952.
Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937–1944.
De Roest RH, Van Der Heijden M, Wesseling FWR, et al. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer. Radiother Oncol 2022; 175:112–121.
Réseau NACRe - Réseau Nutrition Activité physique Cancer Recherche - Pendant le cancer [Internet]. [cited 20 January 2024]. https://www6.inrae.fr/nacre/Pendant-le-cancer/.
French Speaking Society of Clinical Nutrition and Metabolism (SFNEP). Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): summary of recommendations for adults undergoing nonsurgical anticancer treatment. Dig Liver Dis 2014; 46:667–674.
Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open 2021; 6:1–18.
Faravel K, Jarlier M, Senesse P, et al. Trismus occurrence and link with radiotherapy doses in head and neck cancer patients treated with chemoradiotherapy. Integr Cancer Ther 2023; 22:15347354221147283.
COOP-PS [Internet]. [cited 20 January 2024]. https://coopps.ars.sante.fr/coopps/aut/aut_201.do.
Guerdoux-Ninot E, Flori N, Janiszewski C, et al. Assessing dietary intake in accordance with guidelines: useful correlations with an ingesta-Verbal/Visual Analogue Scale in medical oncology patients. Clin Nutr 2019; 38:1927–1935.
Assenat E, Thezenas S, Flori N, et al. Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy. J Pain Symptom Manage 2011; 42:548–556.
Dragan T, Van Gossum A, Duprez F, et al. Patient reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG study. Trials 2022; 23:1036.
Al-Mamgani A, van Rooij P, Verduijn GM, et al. The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer. Laryngoscope 2013; 123:386–393.
Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019; 393:51–60.
Mesía R, Garcia-Saenz JA, Lozano A, et al. Could the addition of cetuximab to conventional radiation therapy improve organ preservation in those patients with locally advanced larynx cancer who respond to induction chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. Int J Radiat Oncol Biol Phys 2017; 97:473–480.
Fuereder T. Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients. Curr Opin Oncol 2022; 34:204–211.
Strojan P, Vermorken JB, Beitler JJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 2016; 38:E2151–E2158.
Martin L, Muscaritoli M, Bourdel-Marchasson I, et al. Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multicohort analysis. J Cachexia Sarcopenia Muscle 2021; 12:1189–1202.
Jensen GL, Cederholm T, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the Global Clinical Nutrition Community. J Parenter Enteral Nutr 2019; 43:32–40.
Mellors K, Ye X, Van Den Brande J, et al. Comparison of prophylactic percutaneous endoscopic gastrostomy with reactive enteral nutrition in patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy: a systematic review. Clin Nutr ESPEN 2021; 46:87–98.
Grant D g, Bradley Pt, Pothier Dd, et al. Complications following gastrostomy tube insertion in patients with head and neck cancer: a prospective multiinstitution study, systematic review and meta-analysis. Clin Otolaryngol 2009; 34:103–112.
Lacroix C, Georges G, Thézenas S, et al. Prospective observational study evaluating complications in adults suffering from cancer and benefiting from Home Parenteral Nutrition. J Nurs Res 2020; 140:107–116.
Hazzard E, Walton K, McMahon AT, et al. Healthcare professionals’ perceptions of feeding tube practices for patients with head and neck cancer across 4 international radiation oncology departments. JPEN J Parenter Enteral Nutr 2020; 44:796–805.
Silander E, Nyman J, Bove M, et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer - a randomized study. Head Neck 2012; 34:1–9.
Quilliot D, Michot N, Germain L, et al. Feasibility, acceptability of enteral tube feeding and self-insertion of a nasogastric tube in the nutritional management of digestive cancers, impact on quality of life. Clin Nutr 2020; 39:1785–1792.
Lewis SL, Brody R, Touger-Decker R, et al. Feeding tube use in patients with head and neck cancer: feeding tube use and chemoradiation. Head Neck 2014; 36:1789–1795.